On August 15, Kelun Pharmaceutical, the leading pharmaceutical company of the large infusion solution, issued an announcement that the company plans to spin off its holding subsidiary Yili Trinion Biotechnology C.
, Lt.
(hereinafter referred to as "Trinning Bio") and list it on the GEM of the Shenzhen Stock Exchang.
The result of the Shenzhen Stock Exchange's deliberation is that Twinings Bio (initial offering) complies with the issuance conditions, listing conditions and information disclosure requirement.
This also means that the IPO of Twinings Bio-GEM has successfully passed the meetin.
What kind of company is Twinings Biological? Judging from the public information, Twinings Bio is one of the main production bases of antibiotic intermediates in Chin.
The prospectus shows that the company is mainly engaged in the research and development and industrialization of biological fermentation technolog.
The products mainly include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates and crude ursodeoxycholic acid (UCDA), et.
Crude cholic acid is used for the synthesis of non-antibiotic drugs (revenues will be formed since 2019), and other products are mainly used in the production of antibiotic.
From the perspective of financial data, the annual report of Kelun Pharmaceutical disclosed that from 2016 to 2018, the operating income realized by Twinings Biotechnology showed a growth trend, increasing from 102 billion yuan to 349 billion yuan, and the net profit also increased from 192 million yuan to 192 million yua.
390 million yua.
However, from 2019 to 2021, the company's performance fluctuated, and the realized operating income was 143 billion yuan, 649 billion yuan, and 232 billion yuan, respectively, with year-on-year changes of -15%, 110%, and -144.
Net profit in the same period was 91 million yuan, 229 million yuan, and 111 million yuan, respectively, with year-on-year changes of -756%, 1558%, and -538.
The 2022 semi-annual report shows that both the revenue and net profit of Twinings Bio have achieved year-on-year growt.
It is expected to achieve operating income of 985 billion yuan, a year-on-year increase of 179%; net profit has doubled to 247 million yuan, a year-on-year increase of 1189.
In this regard, the company stated that mainly in the fourth quarter of last year, due to the impact of the epidemic, the market supply of the company's main products was affected to a certain extent, and the prices of antibiotic intermediate products represented by erythromycin thiocyanate rose significantl.
As of the end of 2021, Trinity Bio's book monetary capital is 510 million yuan, the corresponding short-term borrowing is 700 million yuan, the non-current liabilities due within one year are 879 million yuan, the long-term loan is 092 billion yuan, and the total long-term and short-term debt is 671 billion yua.
Yua.
From the perspective of solvency, during the reporting period, the current ratios of Twinings were 57 times, 38 times, and 25 times, and the industry averages were 84 times, 18 times, and 94 times; the quick ratios were 31 times, 78 times, and 69 time.
times, the industry averages are 53 times, 84 times, and 61 times; the asset-liability ratios are 522%, 597%, and 451%, and the industry averages are 480%, 363%, and 382.
In this IPO, Trinity Biotech plans to raise 600 million yuan, of which 400 million yuan is planned to be used to repay bank loans, and another 200 million yuan is expected to be invested in the "Shanghai Research Institute Construction Project.
It is reported that in the future, Twinings Biotechnology will make use of the advantages of natural resources in Xinjiang and the scientific frontier advantages of setting up a research institute in Shanghai Lingang New Area, and will transform from resource-driven to technological innovation-drive.
Relying on its own technical advantages in independent research and development in the fields of biological fermentation, chemical extraction, enzymatic reaction, energy saving and environmental protection, it focuses on the fields of health care product raw materials, biological pesticides, high value-added natural products, high-end cosmetic raw materials, biodegradable materials and other field.
Taking antibiotic intermediate products as the cornerstone, vigorously develop new products including ursodeoxycholic acid, ergosterol, bisabolol, spinosyn, coenzyme Q10, glabridin,et.
Looking back at its parent company, Kelun Pharmaceutical, the company is mainly engaged in large-volume injections (infusion), small-volume injections (water injection), sterile powder for injection (including sub-packaging powder and freeze-dried powder), tablet.
Research and development, production and sales of pharmaceuticals, capsules, granules, oral liquids, peritoneal dialysate and other drugs, as well as antibiotic intermediates, APIs, pharmaceutical packaging materials and other product.
Kelun Pharmaceutical's operating income in 2021 will be 13 billion yuan, a year-on-year increase of 94%; the net profit after deducting non-return to the parent will be 037 billion yuan, a year-on-year increase of 614.
It is estimated that the profit in the first half of this year will be 820 million yuan to 890 million yuan, an increase of 639%-859% over the same period of the previous yea.
